AAV vector for gene therapy

• US 7,629,322 B2
• Filed: 06/09/2004
• Issued: 12/08/2009
• Est. Priority Date: 06/11/2003
• Status: Expired due to Fees

• Current Assignee: Jürgon Kleinschmidt, Müller, Oliver
• Original Assignee: Jürgon Kleinschmidt, Müller, Oliver
• Inventors: Müller, Oliver, Kleinschmidt, Jürgon
• Primary Examiner(s): Epps-Smith; Janet L
• Assistant Examiner(s): Long; Scott
• Application Number:
  US10/560,268
• Publication Number:
  US 20070036757A1
• Time in Patent Office: 2,008 Days
• Field of Search: None
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/14145 Special targeting system for viral vectors
• CPC Class Codes: C12N 2810/60 from viruses

Abstract

Described are recombinant AAV vectors characterized in that they carry capsid protein modification(s) resulting in a reduced or eliminated heparin binding function. The AAV vectors of the present invention are particularly suitable for gene therapy by systemic application, since (a) transduction of the liver is eliminated or at least drastically reduced and (b) the transduction efficiency of non-hepatic tissues is increased.

Claims

1. A method of gene therapy in a heart muscle tissue of a patient, comprising delivering to the heart muscle tissue of a patient an AAV-2 vector or an AAV-2 particle having a capsid encoded by the AAV-2 vector, wherein the AAV-2 vector comprises mutations R484E and R585E according to the numbering based upon VP1 protein, which are in a heparin binding motif of a capsid protein and cause a reduced or eliminated heparin binding function, and wherein said mutations are located on different subunits of the capsid protein.

2. The method of claim 1, wherein the capsid protein is VP1, VP2, or VP3.

3. The method of claim 2, wherein the capsid protein is VP1.

4. The method of claim 1, wherein said delivering is systemic delivering.